From the Journals

Dual Therapy Boosts Weight Loss in Trial 

A phase 2 trial found greater results with combined bimagrumab and semaglutide than with either therapy alone 

Share

In a phase 2 clinical trial, adults with obesity treated with the combination of bimagrumab and semaglutide achieved significant weight loss compared to those on single therapies. A total of 507 participants, who were overweight with at least one obesity-related complication, were assigned to various treatment groups for up to 72 weeks. The highest dose combination led to an impressive mean weight reduction of 24.2 kg, alongside improvements in metabolic measures and preservation of lean body mass. The study supports further research into combined obesity treatments focusing on both fat and muscle regulation.

Original Source(s)

Dual Therapy Boosts Weight Loss in Trial 

  • by Henry Thomas

  • March 16, 2026

Related Content

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Elevated PFAS Linked to Changes in Blood Lipids 

Serum lipid profiling reveals PFAS-linked shifts in triglyceride and membrane lipid species 

  • March 17, 2026

  • 2 min
Oral Bacteria Linked to Bone Loss in Mouse Study

Researchers find periodontitis-associated microbiota altered gut metabolism and increased osteoclast activity in mice.

  • March 16, 2026

  • 2 min